NEW YORK (GenomeWeb News) – Argenta, a division of Galapagos that specializes in computer-aided drug design, today said that BioFocus has joined its collaboration with Genentech to discover new chemical entities for targets picked by the biopharmaceutical firm.
BioFocus, which also is a division of Galapagos, will provide Genentech with integrated medicinal chemistry, in vitro biology, and ADME services. BioFocus' discovery platform includes cell-based assays, structural biology, chemogenomic and informatics tools, among other capabilities.
Argenta, which was acquired by Galapagos this past February, has been providing drug discovery services for Genentech since 2005.
Terms of the alliance have not been disclosed.